FDA Guidance Will Spur More Companion Diagnostic/Drug Trials – Nuvelo Exec
This article was originally published in The Gray Sheet
Executive Summary
Unclear regulatory pathways for molecular diagnostic tests used to predict patients' response to particular drug therapies can impede the FDA approval process, Abbott Diagnostics Regulatory Affairs Director Matthew Klamrzynski maintained
You may also be interested in...
FDA Pharmacogenetic Regulation: Three Guidances, Fall Workshop
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.